What safety considerations apply to gadolinium contrast in breast MRI?

What safety considerations apply to gadolinium contrast in breast MRI?

• A. It poses no risk to kidneys and can be used without screening
• B. It carries risk of nephrogenic systemic fibrosis in severe kidney disease; screen eGFR; use macrocyclic agents when possible; monitor for adverse reactions
• C. It is contraindicated in all patients with implants
• D. It is only risky in patients under 18

Answer: (B)

Gadolinium-based contrast in breast MRI improves lesion detection by enhancing tissue signals, but it carries a risk for nephrogenic systemic fibrosis in people with severe kidney dysfunction. Because of that, check kidney function with eGFR before giving the contrast. If contrast is used, prefer macrocyclic gadolinium agents since they are more stable and less likely to release gadolinium, reducing NSF risk. Also monitor closely for any adverse reactions during and after the injection. In patients with normal kidney function, the risk is low, but always assess kidney status, especially in those with known kidney disease or dialysis.

Gadolinium-based contrast in breast MRI improves lesion detection by enhancing tissue signals, but it carries a risk for nephrogenic systemic fibrosis in people with severe kidney dysfunction. Because of that, check kidney function with eGFR before giving the contrast. If contrast is used, prefer macrocyclic gadolinium agents since they are more stable and less likely to release gadolinium, reducing NSF risk. Also monitor closely for any adverse reactions during and after the injection. In patients with normal kidney function, the risk is low, but always assess kidney status, especially in those with known kidney disease or dialysis.